scholarly journals Economic Returns Using Risk-rated Budget Analysis for Rabbiteye Blueberry in Georgia

2008 ◽  
Vol 18 (3) ◽  
pp. 506-515 ◽  
Author(s):  
Esendugue Greg Fonsah ◽  
Gerard Krewer ◽  
Kerry Harrison ◽  
Danny Stanaland
Keyword(s):  
Annual Cost ◽  
Maintenance Cost ◽  
Fixed Cost ◽  
Total Annual Cost ◽  
Highbush Blueberry ◽  
Economic Returns ◽  
Vaccinium Ashei ◽  
Budget Analysis ◽  
Full Production ◽  
The Cost

Rabbiteye blueberry (Vaccinium ashei) is the most important type of blueberry grown in Georgia. This species is classified as a highbush blueberry type, but is distinctively different from highbush blueberry (V. corymbosum) in its ability to withstand high temperatures and low-organic–matter soils. However, rabbiteye blueberries, like other fruit crops, are subject to price and yield fluctuation. These volatilities depend on several factors, including the cultivar produced and sold, locality, aggregate productivity, targeted market, and timing. As a result, profit margin is hard to determine. The objective of this study was to estimate economic returns using risk-rated budget analysis for rabbiteye blueberry under Georgia conditions. The first-year establishment and maintenance cost of growing rabbiteye blueberry in Georgia was estimated at $5022.04/acre. Total harvesting and marketing cost in the second year was $719.44/acre. In the third year, total variable and fixed cost was $3487.50/acre. In the full production year (fourth year), the cost was estimated at $4671.17/acre. The compounded and recaptured establishment annual cost was $2736.11/acre. The risk-rated expected returns over total costs 63% of the time were $679.00/acre. The chances of making a profit were 77% and the base budgeted net revenue was $369.00/acre. The total budgeted cost was $0.94/lb. The estimated annual total fixed machinery cost was $698.00/acre. The total annual cost of drip irrigation was $161.15/acre.

scholarly journals Risk-rated Economic Return Analysis for Southern Highbush Blueberries in Soil in Georgia

2007 ◽  
Vol 17 (4) ◽  
pp. 571-579 ◽  
Author(s):  
Esendugue Greg Fonsah ◽  
Gerard Krewer ◽  
Kerry Harrison ◽  
Michael Bruorton
Keyword(s):  
Vaccinium Corymbosum ◽  
Maintenance Cost ◽  
Total Annual Cost ◽  
First Year ◽  
Full Production ◽  
Net Revenue ◽  
Annual Total ◽  
Highbush Blueberries ◽  
Southern Highbush ◽  
The Cost

Southern highbush blueberries (Vaccinium corymbosum × V. darrowii hybrids) are a rapidly emerging crop with a bright future in Georgia; however, blueberries, like other fruit crops, are subject to price and yield fluctuation. These volatilities depend on several factors, including the cultivar produced and sold (i.e., fresh or frozen), locality, aggregate productivity, targeted market, and timing. As a result, profit margin is hard to determine. The objective of this study was to estimate total costs of cultivating southern highbush blueberries in soil under Georgia conditions and determine profitability, if any. Although there are several methods of profit determination, the risk-rated method was adopted for this study. The first-year establishment and maintenance cost of growing southern highbush blueberry in soil in Georgia using high organic matter (greater than 3%) spodic-type or allied sand soil series with supplemental pine bark incorporated was estimated at $9585.55/acre. The second-year establishment and maintenance cost of growing, harvesting, and marketing was $3691.99/acre less return from receipts of $2375.00/acre equal to $1316.99/acre. The third-year establishment and maintenance cost was $7068.20/acre. The total returns for the same year were $9500.00/acre. Subtracting the cost of $7068.20 from $9500.00 gives a net return of $2431.80/acre. The fourth-year cost, which was considered to be the first year of actual full production, was estimated at $13,547.35/acre. The compounded and recaptured establishment annual costs were $2176.43/acre. The risk-rated expected returns over total costs 66% of the time were $5452.65/acre. The chances of making profit were 92% and the base-budgeted net revenue was $6456.00/acre. Total budgeted cost was $3.38/lb. The estimated annual total fixed machinery cost was $290.41/acre. Total annual cost of solid set irrigation was $657.81/acre.

scholarly journals Influence of the variation of the reproduction cycle period of sows on economical efficiency of piglet production

2002 ◽  
Vol 18 (1-2) ◽  
pp. 59-62
Author(s):  
Gordana Vukelic ◽  
Milica Petrovic
Keyword(s):  
Production Technology ◽  
Economic Efficiency ◽  
Annual Cost ◽  
Total Annual Cost ◽  
Cycle Period ◽  
Reproduction Cycle ◽  
Economical Efficiency ◽  
Good Production ◽  
The Cost

In this paper, economic efficiency of the piglet production depending on the total annual cost of sow keeping varying per reproduction cycle was investigated. Investigation refers to the determination of the cost of feeding day per live born and reared piglet in conditions of different duration of nonreproductive period in reproduction cycle. Economical efficiency includes good production technology with production result - piglet that enables profit.

scholarly journals Comparative economics of rural and periurban dairy farming in Kalaburagi district of Karnataka

2019 ◽  
Vol 11 (4) ◽  
pp. 762-767
Author(s):  
Vinayak Patil ◽  
B. S. Reddy ◽  
S. S. Patil ◽  
G. M. Hiremath
Keyword(s):  
Milk Production ◽  
Dairy Farms ◽  
Economic Indicator ◽  
Dairy Farming ◽  
Maintenance Cost ◽  
Fixed Cost ◽  
Crossbred Cows ◽  
Comparative Economics ◽  
The Cost ◽  
Crossbred Cow

Cost of milk production is an important economic indicator in assessing the farm household efficiency in milk production as well as basis for price fixation. The study was undertaken to analyse the cost and returns of milk production in rural and periurban dairy farms of Kalaburagi district of Karnataka. The per day maintenance cost in periurban dairy farms (` 150.64) was highest compared to rural dairy farms (` 91.29)for local cows, crossbred cows and buffaloes. Among total maintenance costs of periurban dairy farming, feed and fodder costs accounted major share (73.49%) followed by labour cost (15.53%) and total fixed cost (7.73%). The return per litre of milk was highest (` 8.91) for crossbred cows followed by buffalo (` 4.82) and local cows (` 0.14). The net return from crossbred cow was more than that of buffalo and local cows indicating higher profitability in rearing crossbred cow in the study area.

Estimation of the cost of MS in Europe: Extrapolations from a multinational cost study

2007 ◽  
Vol 13 (8) ◽  
pp. 1054-1064 ◽  
Author(s):  
P. Sobocki ◽  
M. Pugliatti ◽  
K. Lauer ◽  
G. Kobelt
Keyword(s):  
Annual Cost ◽  
Indirect Costs ◽  
Epidemiological Data ◽  
Cost Data ◽  
Primary Data ◽  
Total Annual Cost ◽  
Cost Study ◽  
Total Cost ◽  
Prevalence Estimates ◽  
The Cost

The present study aims at estimating the total cost of MS in Europe based on actual cost data from nine countries and published epidemiological evidence. The epidemiological data are reported as 12 months prevalence estimates and cost data calculated as annual cost per patient at given levels of disease severity. Cost data are extrapolated to the rest of Europe based on a model, using economic indexes adjusting for price level differences in different sectors between countries. The aggregated annual cost estimates are presented in Euro for 2005. In 28 European countries with a population of 466 million, an estimated 380 000 individuals are affected by MS. The total annual cost of MS in Europe is estimated at 12.5 billion in year 2005, corresponding to a cost of 27 per European inhabitant. Direct costs represent slightly more than half of the total cost (6.0 billion). Informal care is estimated at 3.2 billion, and indirect costs due to morbidity at 3.2 billion. Thus, the largest component of costs is found outside the formal health care sector. Although our model appears to predict costs reasonably well, when comparing to previous national studies not included in the estimates, there are considerable uncertainties when extrapolating cost data across countries even within Europe. These weaknesses can only be overcome by collecting primary data. Multiple Sclerosis 2007; 13: 1054—1064. http://msj.sagepub.com

Underresourced Hospital Infection Control and Prevention Programs: Penny Wise, Pound Foolish?

2007 ◽  
Vol 28 (7) ◽  
pp. 767-773 ◽  
Author(s):  
Deverick J. Anderson ◽  
Kathryn B. Kirkland ◽  
Keith S. Kaye ◽  
Paul A. Thacker ◽  
Zeina A. Kanafani ◽  
...  
Keyword(s):  
Infection Control ◽  
Annual Cost ◽  
Blood Stream Infection ◽  
The United States ◽  
Total Annual Cost ◽  
Community Hospitals ◽  
Control Programs ◽  
Successful Infection ◽  
Hospital Infection Control ◽  
The Cost

Objectives.To estimate the cost of healthcare-associated infections (HAIs) in a network of 28 community hospitals and to compare this sum to the amount budgeted for infection control programs at each institution and for the entire network.Design.We reviewed literature published since 1985 to estimate costs for specific HAIs. Using these estimates, we determined the costs attributable to specific HAIs in a network of 28 hospitals during a 1-year period (January 1 through December 31, 2004). Cost-saving models based on reductions in HAIs were calculated.Setting.Twenty-eight community hospitals in the southeastern region of the United States.Results.The weight-adjusted mean cost estimates for HAIs were $25,072 per episode of ventilator-associated pneumonia, $23,242 per nosocomial blood stream infection, $10,443 per surgical site infection, and $758 per catheter-associated urinary tract infection. The median annual cost of HAIs per hospital was $594,683 (interquartile range [IQR], $299,057-$l,287,499). The total annual cost of HAIs for the 28 hospitals was greater than $26 million. Hospitals budgeted a median of $129,000 (IQR, $92,500-$200,000) for infection control; the median annual cost of HAIs was 4.6 (IQR, 3.4-8.0) times the amount budgeted for infection control. An annual reduction in HAIs of 25% could save each hospital a median of $148,667 (IQR, $74,763-$296,861) and could save the group of hospitals more than $6.5 million.Conclusions.The economic cost of HAIs in our group of 28 study hospitals was enormous. In the modern age of infection control and patient safety, the cost-control ratio will become the key component of successful infection control programs.

scholarly journals The Cost of Managing Type 2 Diabetes Mellitus in Greece: A Retrospective Analysis of 10-Year Patient Level Data “The HERCULES Study”

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Ilias Migdalis ◽  
Grigorios Rombopoulos ◽  
Magdalini Hatzikou ◽  
Christos Manes ◽  
Nikolaos Kypraios ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Annual Cost ◽  
Total Annual Cost ◽  
Patient Level Data ◽  
Patient Level ◽  
Level Data ◽  
The Cost

Objective.This study aimed to estimate the mean annual cost of treating type 2 diabetes mellitus patients (T2DM) including complications and comorbidities in Greece.Design.A noninterventional retrospective study was based on patient level data analysis (bottom-up approach) from medical records, with at least 10-year-follow-up data.Results.The total annual cost per patient for managing diabetes in Greece was estimated at € 7,111 and was, statistically significantly, higher for patients with inadequate glycemic control (Hba1c>7%) versus patients with adequate control (Hba1c=7%) (€ 7,783 versus € 6,366, resp.;   P=0.017). This was mainly attributed to difference in CV hospitalizations between groups 14/111 versus 4/100, respectively,OR=3.46(95% CI: 1.10–10.9) for inadequately controlled patients. The largest component of cost was management of comorbidities, accounting for 48% of costs, and pharmaceutical treatment at 35.9% while only 14.9% was attributed to diabetes treatment per se. Obese men and patients with poor education are the groups with higher treatment costs.Conclusions.This is the first study to capture all cost components and the real burden of diabetes in Greece. Comorbidities were found to account for almost half of total cost, significantly higher in nonoptimally controlled diabetes patients.

scholarly journals Effects of Increase in the Cost of Building Materials on the Delivery of Affordable Housing in South Africa

2021 ◽  
Vol 13 (4) ◽  
pp. 1772
Author(s):  
Bimpe Alabi ◽  
Julius Fapohunda
Keyword(s):  
South Africa ◽  
Affordable Housing ◽  
Building Materials ◽  
Statistical Technique ◽  
Project Managers ◽  
Maintenance Cost ◽  
Cost Increase ◽  
Sequential Mixed Methods ◽  
Adequate Provision ◽  
The Cost

Adequate provision of affordable human settlements is a huge challenge in South Africa since its independence. This paper investigates the effects of the cost increase of building materials on affordable housing delivery in South Africa. With potential solutions for cost minimisation of building materials, with the aim of achieving affordable housing delivery in South Africa are provided. This study uses a sequential mixed methods approach, wherein surveys were conducted among the construction professionals (project managers, site managers architects, site engineers, quantity surveyors, contractors, building materials suppliers, and government workers) in the construction industry within Cape Town, South Africa, who were considered as the research participants. The qualitative data obtained from the survey exercise were analysed using content analysis, while the quantitative data were analysed using a descriptive statistical technique on SPSS. The findings attained show fluctuation in construction cost and a rise in maintenance cost (caused by poor workmanship) as significant effects in the cost increase of building materials for affordable housing delivery. Adequate application of the recommendations given in this study will minimise the effects of high cost of building materials and enhance affordable housing delivery. Appropriate handling of the findings given in this study will reduce the effects of the high cost of building materials and augment timely delivery of affordable housing and stakeholders’ satisfaction.

scholarly journals Analysis and Optimization of a Novel Hexagonal Waveguide Concentrator for Solar Thermal Applications

Energies ◽  
2021 ◽  
Vol 14 (8) ◽  
pp. 2146
Author(s):  
Karunesh Kant ◽  
Karthik Nithyanandam ◽  
Ranga Pitchumani
Keyword(s):  
Industrial Process ◽  
Cost Effective ◽  
Solar Irradiation ◽  
Maintenance Cost ◽  
Solar Concentrator ◽  
Thermal Desalination ◽  
Process Heat ◽  
Solar Thermal Applications ◽  
The Cost ◽  
Operation And Maintenance Cost

This paper analyzes a novel, cost-effective planar waveguide solar concentrator design that is inspired by cellular hexagonal structures in nature with the benefits of facile installation and low operation and maintenance cost. A coupled thermal and optical analysis of solar irradiation through an ideal hexagonal waveguide concentrator integrated with a linear receiver is presented, along with a cost analysis methodology, to establish the upper limit of performance. The techno-economic model, coupled with numerical optimization, is used to determine designs that maximized power density and minimized the cost of heat in the temperature range of 100–250 °C, which constitutes more than half of the industrial process heat demand. Depending on the incident solar irradiation and the application temperature, the cost of heat for the optimal design configuration ranged between 0.1–0.27 $/W and 0.075–0.18 $/W for waveguide made of ZK7 glass and polycarbonate, respectively. A techno-economic analysis showed the potential of the technology to achieve cost as low as 80 $/m2 and 61 $/m2 for waveguide made of ZK7 glass and polycarbonate material, respectively, which is less than half the cost of state-of-the-art parabolic trough concentrators. Overall, the hexagonal waveguide solar concentrator technology shows immense potential for decarbonizing the industrial process heat and thermal desalination sectors.

A comprehensive assessment of the cost of multiple sclerosis in the United States

1998 ◽  
Vol 4 (5) ◽  
pp. 419-425 ◽  
Author(s):  
Kathryn Whetten-Goldstein ◽  
Frank A Sloan ◽  
Larry B Goldstein ◽  
Elizabeth D Kulas
Keyword(s):  
Multiple Sclerosis ◽  
Health Care ◽  
Health Insurance ◽  
Informal Care ◽  
Annual Cost ◽  
Lifetime Cost ◽  
The United States ◽  
Personal Health ◽  
Secondary Sources ◽  
The Cost

Comprehensive data on the costs of multiple sclerosis is sparse. We conducted a survey of 606 persons with MS who were members of the National Multiple Sclerosis Society to obtain data on their cost of personal health services, other services, equipment, and earnings. Compensation of such cost in the form of health insurance, income support, and other subsidies was measured. Survey data and data from several secondary sources was used to measure costs incurred by comparable persons without MS. Based on the 1994 data, the annual cost of MS was estimated at over $34 000 per person, translating into a conservative estimate of national annual cost of $6.8 billion, and a total lifetime cost per case of $2.2 million. Major components of cost were earnings loss and informal care. Virtually all persons with MS had health insurance, mostly Medicare/Medicaid. Health insurance covered 51 per cent of costs for services, excluding informal care. On average, compensation for earnings loss was 27 per cent. MS is very costly to the individual, health care system, and society. Much of the cost (57 per cent) is in the form of burdens other than personal health care, including earnings loss, equipment and alternations, and formal and informal care. These costs often are not calculated.

Abstract P241: One-Year Cost-Effectiveness of Cytochrome P450 2C19 Genotype-Guided Antiplatelet Therapy in Patients With Acute Coronary Syndromes

2011 ◽  
Vol 4 (suppl_1) ◽  
Author(s):  
Scott L Charland ◽  
Barnabie C Agatep ◽  
Daniel C Malone ◽  
Eric J Stanek
Keyword(s):  
Cytochrome P450 ◽  
Cost Effectiveness ◽  
Antiplatelet Therapy ◽  
Annual Cost ◽  
Extensive Metabolizers ◽  
Cyp2c19 Genotype ◽  
Event Management ◽  
Test Cost ◽  
Cytochrome P450 2C19 ◽  
The Cost

OBJECTIVES: Cytochrome P450 2C19 (CYP2C19) genotype has been shown to affect cardiovascular (CV) outcomes for clopidogrel but not prasugrel. This study evaluates the cost-effectiveness of CYP2C19-guided vs. routine antiplatelet therapy in ACS patients. METHODS: We constructed a literature-based, decision analytic, Markov model (TreeAge 2009) to estimate the cost-effectiveness of CYP2C19-guided aspirin plus either clopidogrel or prasugrel therapy vs. no genotyping. Post-initial ACS CV events were based on the TRITON-TIMI 38 study and related costs were derived primarily using 2007 Healthcare Cost and Utilization Project DRGs for nonfatal MI and stroke, CV death, intracranial hemorrhage, other life-threatening bleed, and minor bleed. Additional costs and disease-state utilities were obtained from other published sources. All costs were adjusted to 2009 $US using the Consumer Price Index medical care component. The model allowed for clopidogrel/prasugrel discontinuation and aspirin monotherapy. Model sensitivity was assessed using 1-way and multi-way analysis of influential parameters. RESULTS: The base case model demonstrated that CYP2C19 genotype guided antiplatelet therapy yielded lower overall annual cost and greater efficacy vs. no genotyping ( Table ). The model was sensitive to (in declining order): clopidogrel cost/day ($1 to $5.78), prasugrel cost/day ($4.09 to $ 6.81), % CYP2C19 extensive metabolizers on clopidogrel (60% to 100%), CYP2C19 test cost ($60 to $250), and monthly CV event management cost. A threshold value for clopidogrel at <$2.14/day favored the no genotyping strategy. However, the genotyping strategy was dominant when clopidogrel cost =$1/day and a CYP2C19 test cost threshold of <$125 on 2-way analysis. CONCLUSIONS: CYP2C19 genotype-guided clopidogrel or prasugrel therapy is cost-effective for up to 1 year in ACS patients, and can remain a preferred strategy at a hypothetical generic clopidogrel cost of $1.00/day. Table Strategy1 Annual Cost Incremental Cost Quality Adjusted Life Year (QALY) Incremental QALY Cost/QALY Incremental Cost Effectiveness (ICER) CYP2C19 Genotype-Guided $ 3,211 0.7212 $ 4,452 No Gentoyping $ 3,331 $120 0.6767 - (0.0445) $ 4,921 (Dominated) 1Base case values:Drug wholesale acquisition cost/day: clopidogrel $4.62, prasugrel $5.45; Baseline post-ACS utility = 0.83; Monthly cost for post-CV event management = $351; CYP2C19 genotyping =$185; After genotyping: 80% of extensive metabolizers, 20% of intermediate metabolizers and 10% of poor metabolizers on clopidogrel; 80% on clopidogrel without genotyping; Willingness to pay = $200

Sign in / Sign up

Export Citation Format

Share Document